The Effect Of Baricitanib Usage On The Clinical And Biochemical Profiles Of COVID-19 Patients- A Retrospective Observational Study

IntroductionCoronaviruses typically cause influenza like illness which progresses to ARDS along with other systemic manifestations. India is experiencing its second wave with a huge surge in the number of cases exponentially causing huge impact on health care infrastructure and the demand supply chain. As a result several new modalities have been used, one of which is the use of remdesivir and baricitinib . Hence this study is aimed at finding out the clinical and biochemical profile of the patients who have received the combination Materials and MethodsAll the patients who have received the combination meeting the inclusion and exclusion criteria have been included in the study. A total of 31 participants were included and their records were retrospectively analyzed. ResultsThere was a significant reduction in the oxygen requirement, CRP and IL-6 levels with p values<0.05. However, in the non-survivors group, there was no statistically significant reduction. Serial monitoring of NLR ratio showed increase towards the fifth day, especially in the non-survivor group it was as high as 41.24. The mortality rate was found to be 10% and the cause being secondary sepsis in all of them. ConclusionThe ACTT-2 trail has proved the efficacy of the use of the remdesivir and baricitinib combination with mortality benefit. In our study we found similar results which was well co-related with clinical and biochemical parameters like CRP and IL-6 especially in people with co-morbidites.